Shigella Sonnei

• For temporary relief of fever and chills. Promotes a productive wet cough and the coughing up of phlegm.ICD-10: R05.9

DIRECTIONS: 5 drops three times daily (under tongus), 5 days per week (between meals, food and beverage), unless otherwise directed by health provider. Consult a physician for use in children under 12 years of age.

If pregnant or breast-feeding, ask a health professional before use. Keep out of reach of children. In case of overdose, get medical help or contact a Poison Control Center right away. Do not use if tamper evident seal is broken or missing. Store in a cool, dry place.

Recent PubMed references pinned to Shigella Sonnei as a MeSH major topic. Citations link to pubmed.ncbi.nlm.nih.gov.

• Genome-wide analysis exploring mechanisms used by Shigella sonnei to survive long-term nutrient starvation.
  mSystems · 2026 · Matanza XM, Leung PB, Torraca V, et al.
  PMID 41837654DOI 10.1128/msystems.00088-26
• Protocol to identify the signaling network of nucleotide second messengers in Shigella sonnei.
  STAR protocols · 2026 · Cui B, Chen X, Wang M, et al.
  PMID 41671092DOI 10.1016/j.xpro.2026.104353
• Immunogenicity evaluation of altSonflex1-2-3 Shigella vaccine across mice, rats, and rabbits to inform human translational insights.
  Frontiers in immunology · 2025 · Caradonna V, Alfini R, Pinto M, et al.
  PMID 41646979DOI 10.3389/fimmu.2025.1740821
• The natural history of the emergence of sexually transmissible shigellosis.
  Microbial genomics · 2026 · Mason LCE, Jawed F, Fruth A, et al.
  PMID 41563836DOI 10.1099/mgen.0.001607
• Emerging Ceftriaxone Resistance in Paediatric Shigella sonnei: A 10-Year Retrospective Study.
  Acta paediatrica (Oslo, Norway : 1992) · 2026 · Skripai A, Katz A, Lellouche J, et al.
  PMID 41555678DOI 10.1111/apa.70449
• A public resource of 15 genomically characterized representative strains of Shigella sonnei.
  Microbial genomics · 2026 · Miles SL, Hawkey J, Vezina B, et al.
  PMID 41525141DOI 10.1099/mgen.0.001596
• Shigella sonnei and Shigella flexneri: Epidemiology supporting development of cross-protective vaccines.
  Human vaccines & immunotherapeutics · 2026 · Caradonna V, Hunyady A, Nakakana U, et al.
  PMID 41521552DOI 10.1080/21645515.2025.2603736
• Extended spectrum β-lactamase and integron genes among Shigella flexneri and Shigella sonnei isolated from children with diarrhea in shiraz, Southwest Iran.
  BMC pediatrics · 2025 · Farhadi K, Zomorodi AR, Hassannezhad M, et al.
  PMID 41121044DOI 10.1186/s12887-025-06074-w

The 10 most recently updated of 19 ClinicalTrials.gov registrations naming Shigella Sonnei as an intervention. Registration is not evidence of efficacy or safety — reference crosswalk only.

• Long-Term Immunogenicity of the altSonflex1-2-3 Shigella Vaccine in African Children
  Not yet recruiting · Phase 2 · Interventional · 528 enrolled · GlaxoSmithKline
  NCT07320716updated 2026-01-06
• A Study on the Safety and Immune Responses to the GVGH altSonflex1-2-3 Vaccine Against Shigellosis in Adults, Children, and Infants
  Completed · Phase 1 · Interventional · 551 enrolled · GlaxoSmithKline
  NCT05073003updated 2025-12-04
• Phase 2 Shigella Vaccine and Challenge
  Completed · Phase 2 · Interventional · 69 enrolled · National Institute of Allergy and Infectious Diseases (NIAID)
  NCT04242264updated 2025-04-24
• Shigella Sonnei 53G Human Infection Study in Kenyan Adults
  Recruiting · Phase 1 · Interventional · 70 enrolled · University of Oxford
  NCT05959616updated 2025-03-13
• Controlled Human Infection Model Challenge/Rechallenge
  Completed · Phase 1 · Interventional · 46 enrolled · PATH
  NCT04992520updated 2025-01-31
• A Study to Evaluate the Efficacy, Safety and Immunogenicity of a Vaccine Designed to Protect Against Infection With Shigella Sonnei in Healthy Adults
  Completed · Phase 2 · Interventional · 71 enrolled · GlaxoSmithKline
  NCT03527173updated 2020-07-28
• Shigella WRSS1 Vaccine Trial in Bangladesh
  Completed · Phase 1 · Interventional · 16 enrolled · PATH
  NCT02934178updated 2020-03-31
• Shigella Sonnel O-SPC/rBRU Conjugate Vaccine
  Completed · Phase 1 · Interventional · 60 enrolled · Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
  NCT01369927updated 2019-12-16
• A Study to Evaluate Safety and Immunogenicity of 1 Booster Dose of 1790GAHB Vaccine in Healthy Adults Primed With 3 Doses of 1790GAHB Vaccine in Study H03_01TP Compared to 1 Vaccination of 1790GAHB in Either Subjects Who Received Placebo in the Same Study or naïve Subjects Not Part of H03_01TP Study
  Completed · Phase 1 · Interventional · 35 enrolled · GlaxoSmithKline
  NCT03089879updated 2019-06-28
• Dose-Finding Study of Lyophilized Shigella Sonnei 53G Challenge Strain
  Completed · Phase 1 · Interventional · 56 enrolled · PATH
  NCT02816346updated 2019-06-03

Frequently asked questions

What is Shigella Sonnei used for?

According to FDA labeling, Shigella Sonnei carries indications including: For temporary relief of fever and chills. Promotes a productive wet cough and the coughing up of phlegm.. This is a reference summary of labeled uses, not medical advice or a treatment recommendation.